Drug Interaction:
Ketoconazole. iytraconazole, Atazanavir, indinavir, nelfinavir, retonavir, seqquinavir, Clarithromycin, Telithromycin, Nefazodone, sulonylureas
Indication:
Proprietary Name- Onglyza
Established Name - Saxagliptin - Dipetidyl peptidase -4 (DPP4) inhibitor
Applicant- Bristol Myers Squibb Co.
Indication-
Adjunct to diet and excercise to improve glycemic control in adults with
type 2 diabetes mellitus
Dosage-
2.5mg or 5mg once daily
Approved by FDA on 31-7-2009 (Ref- FDA approved List- 2009)
New Drugs Approved by (DCI) Drug Controller GENERAL - India For Marketing
(Ref- IDMA Publication)
Name of Drug Indication Date of Approval
Saxagliptin Hcl 2.5mg/5mg 24-10-2009
Tablets
As an adjunct to diet and excercise to improve Glycemic Control
in adults with Type-2 Diabetes Mellitus.
It should not be used for the treatment of Type-1 Diabetes Mellitus
or Diabetic Ketoacidosis,as it would not be effective in these settings
Treatment of Type II diabetes Patients inadequately controlled by diet
Adverse Reaction:
URTI infection, UTI , GI upset, sinusitis, Nasoglycaemia, peripheral oedema
Contra-Indications:
Diabetic ketoacidosis Moderate to severe renal impairment Severe hepatic impairmentCongestive heart failure Pregnancy. lactation Special precautions- Immuocomprised, moderate hepatic impairment Monitor renal function Elderly patients
Manufacturer Details